Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 56

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 56
---
 with good reason in connection with a change in control, represents continued payment of base salary in accordance with our current payroll practices for 24 months for Mr. Peetz and 18 months for the other named executive officers.

(2) In the event of termination without cause or with good reason in connection with a change in control, represents a lump sum cash payment equal to the named executive officer’s target bonus for the applicable fiscal year, pro-rated based on the date of termination.

(3) The value of restricted stock unit award vesting acceleration is based on the closing price of $41.35 per share of our common stock as of December 31, 2024.

#### 46Mirum Pharmaceuticals2025 Proxy Statement

#### TABLE OF CONTENTS

#### Executive Compensation

#### Pay Ratio Disclosure
Pursuant to Item 402(u) of Regulation S-K, presented below is the ratio of annual total compensation of our CEO to the annual total compensation of our median employee (except our CEO). The ratio presented below is a reasonable estimate calculated in a manner consistent with Item 402(u). The SEC’s rules for identifying the median compensated employee and calculating the pay ratio based on that employee’s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. As a result, the pay ratio reported by other companies may not be comparable to the pay ratio reported below, as other companies have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.

For fiscal year 2024,

• the median of the annual total compensation of all employees of the Company (other than the CEO) was $393,477; and

• the annual total compensation of the CEO, as reported in the Summary Compensation Table included in this Proxy Statement, was $6,598,551.

Based on this information, the ratio of the annual total compensation of the CEO to the median of the annual total compensation of all employees was 17 to 1.

We identified our median compensated employee from all full-time and part-time employees who were included as employees on our payroll records as of a determination date of December 31, 2024. We did not include any contractors or other non-employee workers in our employee population. We used a consistently applied compensation measure consisting of annual base salary, annual bonus or commission targets, and the grant date value of equity awards granted during fiscal year 2024